tiprankstipranks
Trending News
More News >

BioXcel Therapeutics initiated with a Buy at Lucid Capital

Lucid Capital initiated coverage of BioXcel Therapeutics (BTAI) with a Buy rating and $66 price target BioXCel is expanding the use of its approved agitation drug, Igalmi, for at-home use and for Alzheimer’s disease, the analyst tells investors in a research note. The firm says there are 7M patients diagnosed with Alzheimer’s disease in the U.S. alone and the numbers are expected to double every 20 years with the aging population. It sees blockbuster potential for Igalmi.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1